Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 2/2016

Open Access 01-08-2016

Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis

Authors: Y. C. Lau, Q. Xiong, P. Ranjit, G. Y. H. Lip, A. D. Blann

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2016

Login to get access

Abstract

As heart failure, coronary artery disease and atrial fibrillation all bring a risk of thrombosis, anti-thrombotic therapy is recommended. Despite such treatment, major cardiovascular events such as myocardial infarction and stroke still occur, implying inadequate suppression of thrombus formation. Accordingly, identification of patients whose haemostasis remains unimpaired by treatment is valuable. We compared indices for assessing thrombogenesis and fibrinolysis by two different techniques in patients on different anti-thrombotic agents, i.e. aspirin or warfarin. We determined fibrin clot formation and fibrinolysis by a microplate assay and thromboelastography, and platelet marker soluble P selectin in 181 patients with acute or chronic heart failure, coronary artery disease who were taking either aspirin or warfarin. Five thromboelastograph indices and four microplate assay indices were different on aspirin versus warfarin (p < 0.05). In multivariate regression analysis, only microplate assay indices rate of clot formation and rate of clot dissolution were independently related to aspirin or warfarin use (p ≤ 0.001). Five microplate assay indices, but no thrombelastograph index, were different (p < 0.001) in aspirin users. Three microplate assay indices were different (p ≤ 0.002) in warfarin users. The microplate assay indices of lag time and rate of clot formation were abnormal in chronic heart failure patients on aspirin, suggesting increased risk of thrombosis despite anti-platelet use. Soluble P selectin was lower in patients on aspirin (p = 0.0175) but failed to correlate with any other index of haemostasis. The microplate assay shows promise as a tool for dissecting thrombogenesis and fibrinolysis in cardiovascular disease, and the impact of antithrombotic therapy. Prospective studies are required to determine a role in predicting thrombotic risk.

Literature
  1. Liu L, Eisen HJ (2014) Epidemiology of heart failure and scope of the problem. Clin Cardiol 32:1–8View Article
  2. Lip GY, Lane DA (2015) Stroke prevention in atrial fibrillation: a systematic review. JAMA 313:1950–1962View ArticlePubMed
  3. Crea F, Liuzzo G (2013) Pathogenesis of acute coronary syndromes. J Am Coll Cardiol 61:1–11View ArticlePubMed
  4. Harinstein ME, Filippatos GS, Gheorghiade M (2009) Acute heart failure syndromes: epidemiology, risk stratification and prognostic factors. Acute Card Care. 11:77–82View ArticlePubMed
  5. Gurbel PA, Tantry US (2014) Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. JACC Heart Fail. 2:1–14View ArticlePubMed
  6. Fifth Joint Task Force of the European Society of Cardiology (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Prev Cardiol 19:585–667View Article
  7. Homma S, Thompson JL, Pullicino PM, WARCEF Investigators et al (2012) Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 17(366):1859–1869View Article
  8. Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625–651View ArticlePubMed
  9. Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M, British Committee for Standards in Haematology (2013) Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol. 35:1–13View ArticlePubMed
  10. Keeling D, Baglin T, Tait C et al (2011) British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol 154:311–324View ArticlePubMed
  11. Blann AD (2014) Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. Br J Biomed Sci 71:158–167View ArticlePubMed
  12. Luddington RJ (2005) Thrombelastography/thromboelastometry. Clin Lab Haematol 27:81–90View ArticlePubMed
  13. Jones AJ, Meunier AM (1990) A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modelling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Thromb Haemost 64:455–463PubMed
  14. Incampo F, Carrieri C, Galasso R, Marino R, Ettorre CP, Semeraro N, Colucci M (2014) Co-administration of low molecular weight heparin enhances the profibrinolytic effect of warfarin through different mechanisms. Thromb Res 133:634–639View ArticlePubMed
  15. Ranjit P, Lau Y, Lip GY, Blann AD (2015) Development and validation of a new assay for assessing clot integrity. Vasc Pharmacol 71:102–107View Article
  16. Traverso CI, Arcelus JI, Caprini JA (1995) Role of thromboelastography in evaluating other anticoagulant agents: warfarin and heparin-dihydroergotamine. Semin Thromb Hemost 21(Suppl 4):59–62PubMed
  17. Dias JD, Norem K, Doorneweerd DD, Thurer RL, Popovsky MA, Omert LA (2015) Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med 139:665–673View ArticlePubMed
  18. Darlington A, Ferreiro JL, Ueno M et al (2011) Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thromb Haemost 106:67–74View ArticlePubMed
  19. Franchi F, Hammad JS, Rollini F, Tello-Montoliu A, Patel R, Darlington A et al (2015) Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists. J Thromb Thrombolysis 40:118–125View ArticlePubMed
  20. Blann AD, Nadar SK, Lip GY (2003) The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 24:2166–2179View ArticlePubMed
  21. McCully SP, Fabricant LJ, Kunio NR et al (2013) The International Normalized Ratio overestimates coagulopathy in stable trauma and surgical patients. J Trauma Acute Care Surg. 75:947–953View ArticlePubMed
  22. Altman DG (1991) Practical statistics for medical research. Chapman and Hall, London
  23. Machin D, Campbell M (1987) Statistical table for the design of clinical trials. Blackwell Scientific, Oxford
  24. Welsh KJ, Padilla A, Dasgupta A, Nguyen AN, Wahed A (2014) Thromboelastography is a suboptimal test for determination of the underlying cause of bleeding associated with cardiopulmonary bypass and may not predict a hypercoagulable state. Am J Clin Pathol 142:492–497View ArticlePubMed
  25. Louis SG, Van PY, Riha GM et al (2014) Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial. J Trauma Acute Care Surg. 76:937–942View ArticlePubMed
  26. Gebhart J, Laczkovics C, Posch F, Ay C, Reitter-Pfoertner SE, Haslacher H, Muszbek L, Wolberg AS, Pabinger I (2015) Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause. Ann Hematol 94:1301–1310View ArticlePubMed
  27. Talens S, Malfliet JJ, Rudež G, Spronk HM, Janssen NA, Meijer P, Kluft C, de Maat MP, Rijken DC (2012) Biological variation in tPA-induced plasma clot lysis time. Thromb Haemost 108:640–646View ArticlePubMed
  28. Ząbczyk M, Majewski J, Karkowski G, Malinowski KP, Undas A (2015) Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3 days of treatment: Relation to coagulation factors and thrombin generation. Thromb Res. doi:10.​1016/​j.​thromres.​2015.​08.​007
  29. Warzok F, Steiner M, Blann AD, Weber F, Urbaszek W, Schuff-Werner P (1999) Immediate and late effects of coronary angiography on soluble endothelial cell markers and P-selectin in patients with and without coronary artery disease. Blood Coagul Fibrinolysis 10:381–387View ArticlePubMed
  30. O’Connor CM, Gurbel PA, Serebruany VL (1999) Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 83:1345–1349View ArticlePubMed
  31. Choudhury A, Chung I, Blann AD, Lip GY (2007) Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of “healthy control subjects” and “disease control subjects” in sinus rhythm. J Am Coll Cardiol 49:1957–1964View ArticlePubMed
  32. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP (2004) The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 15:117–125View ArticlePubMed
  33. Valdes V, Nardi MA, Elbaum L, Berger JS (2015) Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand. J Thromb Thrombolysis 40:83–87View ArticlePubMed
  34. Fareed J, Hoppensteadt DA, Leya F, Iqbal O, Wolf H, Bick R (1998) Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 44:1845–1853PubMed
  35. Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD, Beevers DG (1996) Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 94:425–431View ArticlePubMed
  36. Harr JN, Moore EE, Chin TL et al (2013) Platelets are dominant contributors to hypercoagulability after injury. J Trauma Acute Care Surg. 74:756–762View ArticlePubMedPubMed Central
  37. Lu D, Owens J, Kreutz RP (2013) Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes. Thromb Res 132:e94–e98View ArticlePubMedPubMed Central
  38. Neyens R, Bohm N, Cearley M, Andrews C, Chalela J (2014) Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG(®)) to guide decision-making. J Thromb Thrombolysis 37:80–83View ArticlePubMed
  39. Aleman MM, Gardiner C, Harrison P, Wolberg AS (2011) Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost 9:2251–2261View ArticlePubMedPubMed Central
  40. Undas A, Nycz K, Pastuszczak M, Stompor T, Zmudka K (2010) The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome. Blood Coagul Fibrinolysis 21:522–527View ArticlePubMed
Metadata
Title
Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis
Authors
Y. C. Lau
Q. Xiong
P. Ranjit
G. Y. H. Lip
A. D. Blann
Publication date
01-08-2016
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2016
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1344-5

Other articles of this Issue 2/2016

Journal of Thrombosis and Thrombolysis 2/2016 Go to the issue

OriginalPaper

Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients

ReviewPaper

Novel oral anticoagulants for heparin-induced thrombocytopenia

OriginalPaper

Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC–MS/MS method

OriginalPaper

Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13

Report

Fibrin structure in organized thrombotic material removed during pulmonary artery endarterectormy: the effect of vessel calibre

OriginalPaper

Pregnancy-associated plasma protein-A promotes TF procoagulant activity in human endothelial cells by Akt–NF-κB axis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits